SPOTLIGHT: GSK dumps obesity partnership

GlaxoSmithKline has pulled out of a collaboration with Sweden's Biovitrum to develop an anti-obesity drug. Biovitrum says it won't further develop the compounds for obesity on its own. Report

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.